Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of Olaparib or MNA on bone marrow derived macrophage gene expression during induction

ABSTRACT: The effect of Olaparib or MNA on bone marrow derived macrophage gene expression during induction

PROVIDER: PRJNA865448 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20761268_1.fastq.gz	Fastqsanger.gz
	SRR20761268_2.fastq.gz	Fastqsanger.gz
	SRR20761269_1.fastq.gz	Fastqsanger.gz
	SRR20761269_2.fastq.gz	Fastqsanger.gz
	SRR20761270_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

The effect of Olaparib or MNA on bone marrow derived macrophage gene expression during induction

Project description:To investigate the effect of olaparib or MNA on macrophage, we treated bone marrow with olaparib or MNA during BMDM induction for 6 days.

2022-08-05 | GSE210378 | GEO

Olaparib

Project description:Olaparib

| PRJEB6685 | ENA

Bone marrow derived macrophage vs peritoneal macrophage

Project description:Bone marrow derived macrophage vs peritoneal macrophage

| PRJNA414129 | ENA

Genome-wide analysis of enzalutamide- and/or olaparib-responsive gene expression in prostate cancer cells

Project description:Analysis of enzalutamide- and/or olaparib-responsive gene expression in prostate cancer cells. The hypothesis tested in the present study was that enzalutamide influences the expression of genes that are involved in important bioprocesses in prostate cance rcells, including DNA damage response genes and this effect may synergize with poly(ADP-ribose) polymerase inhibitor olaparib in cytotoxicity to prstate cancer cells. prostate cancer cells were pretreated with enzalutamide or vehicle control DMSO for 24 h, followed by treatment with enzalutamide, olaparib, enzalutamide+olaparib, or vehicle control DMSO for 48 h. Gene expression in enzalutamide+olaparib-treated cells was compared with taht in vehicle control- and single agent-treated cells.

2016-07-03 | E-GEOD-69249 | biostudies-arrayexpress

Epibryaceae sp. MNA-CCFEE 6094 isolate:MNA-CCFEE 6094

Project description:Epibryaceae sp. MNA-CCFEE 6094 Minimal Draft genome sequencing

| PRJNA1080919 | ENA

Capnodiales sp. MNA-CCFEE 6580 isolate:MNA-CCFEE 6580

Project description:Capnodiales sp. MNA-CCFEE 6580 Minimal Draft genome sequencing

| PRJNA1080917 | ENA

Chaetothyriales sp. MNA-CCFEE 5317 isolate:MNA-CCFEE 5317

Project description:Chaetothyriales sp. MNA-CCFEE 5317 Minimal Draft genome sequencing

| PRJNA1080918 | ENA

Activation of Wnt signaling promotes olaparib resistant ovarian cancer.

Project description:Sequencing of olaparib-resistant PEO1 derivatives (C4, C5, C10 and C18) and parental PEO1 (P1 and P2) cells was performed in order to determine mechanisms of acquired resistance in the resistant cell lines. PEO1 parental cell lines were authenticated prior to sequencing. PEO1 parental were confirmed to be BRCA2-mutated (5139C>G). Olaparib PEO1 resistant cells were generated through a step-wise escalation of olaparib (10nM to 8uM olaparib). In olaparib resistant lines an increase canonical Wnt signaling and loss of of non-canonical Wnt signaling was observed.

2018-07-28 | GSE117765 | GEO

Transcriptome profiling of Olaparib-resistant (OlapR) prostate cancer cell lines

Project description:Acquisition of resistance to the PARP inhibitor, Olaparib, constitutes a major challenge for the treatment of advanced prostate cancer. The purpose of this study was to identify molecular targets responsible for the development of acquired Olaparib resistance in advanced prostate cancer. Towards this goal, next-generation sequencing (NGS)-based gene expression profiling (RNA-Sequencing; RNA-Seq) was performed on castration-sensitive prostate cancer (CSPC)/Olaparib-sensitive LNCaP cells, castration-sensitive prostate cancer (CSPC)/Olaparib-resistant LN-OlapR cells, castration-resistant prostate cancer (CSPC)/Olaparib-sensitive C4-2B cells, and castration-resistant prostate cancer (CSPC)/Olaparib-resistant 2B-OlapR cells.

2023-12-06 | GSE249514 | GEO

Extremus antarcticus strain:MNA-CCFEE 451 | isolate:MNA-CCFEE 451

Project description:Extremus antarcticus MNA-CCFEE 451 Minimal Draft genome sequencing

| PRJNA1080885 | ENA